Difference between revisions of "Lapatinib (Tykerb)"
Jump to navigation
Jump to search
m |
|||
| Line 18: | Line 18: | ||
* 3/13/2007: Initial FDA approval in combination with [[Capecitabine (Xeloda) | capecitabine]], for the treatment of patients with advanced or metastatic [[breast cancer]] whose tumors [[Biomarkers#Overexpression|overexpress]] [[Biomarkers#HER2|HER2]] and who have received prior therapy including an [[:Category:Anthracyclines | anthracycline]], a [[:Category:Taxanes | taxane]], and [[Trastuzumab (Herceptin) | trastuzumab]]. | * 3/13/2007: Initial FDA approval in combination with [[Capecitabine (Xeloda) | capecitabine]], for the treatment of patients with advanced or metastatic [[breast cancer]] whose tumors [[Biomarkers#Overexpression|overexpress]] [[Biomarkers#HER2|HER2]] and who have received prior therapy including an [[:Category:Anthracyclines | anthracycline]], a [[:Category:Taxanes | taxane]], and [[Trastuzumab (Herceptin) | trastuzumab]]. | ||
* 1/29/2010: New indication in combination with [[Letrozole (Femara) | letrozole]] for the treatment of postmenopausal women with [[Biomarkers#HR|hormone receptor]] [[Biomarkers#Expression|positive]] metastatic [[breast cancer]] that [[Biomarkers#Overexpression|overexpresses]] the [[Biomarkers#HER2|HER2 receptor]] for whom hormonal therapy is indicated. | * 1/29/2010: New indication in combination with [[Letrozole (Femara) | letrozole]] for the treatment of postmenopausal women with [[Biomarkers#HR|hormone receptor]] [[Biomarkers#Expression|positive]] metastatic [[breast cancer]] that [[Biomarkers#Overexpression|overexpresses]] the [[Biomarkers#HER2|HER2 receptor]] for whom hormonal therapy is indicated. | ||
| + | |||
| + | ==History of changes in EMA indication== | ||
| + | * 6/10/2008: Initial marketing authorization as Tyverb. | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' GW572016 | *'''Code name:''' GW572016 | ||
| − | *'''Brand | + | *'''Brand names:''' Abnib, Combinib, Etibo, Herduo, Herlapsa, Hertab, Lapanix, Lapatem, Tykerb, Tyverb |
==References== | ==References== | ||
| Line 36: | Line 39: | ||
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
| + | [[Category:EMA approved in 2008]] | ||
[[Category:FDA approved in 2007]] | [[Category:FDA approved in 2007]] | ||
Revision as of 14:47, 4 December 2021
General information
Class/mechanism: EGFR/HER2 tyrosine kinase inhibitor; 4-anilinoquinazoline inhibitor of the intracellular tyrosine kinase domains of EGFR (epidermal growth factor receptor/ErbB1) and HER2 (human epidermal growth factor receptor 2/ErbB2), which drive proliferation in certain malignancies.
[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Lapatinib (Tykerb) patient drug information[4]
- Lapatinib (Tykerb) patient drug information (Chemocare)[5]
- Lapatinib (Tykerb) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 3/13/2007: Initial FDA approval in combination with capecitabine, for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.
- 1/29/2010: New indication in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated.
History of changes in EMA indication
- 6/10/2008: Initial marketing authorization as Tyverb.
Also known as
- Code name: GW572016
- Brand names: Abnib, Combinib, Etibo, Herduo, Herlapsa, Hertab, Lapanix, Lapatem, Tykerb, Tyverb